Janssen Pharmaceutical Collaborates with Stiching International Dispensary Association - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Janssen Pharmaceutical Collaborates with Stiching International Dispensary Association


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 5

Johnson & Johnson reported its affiliate Janssen Pharmaceutical NV has entered into a collaboration with the Stiching International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF), to facilitate access to the company’s anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health, to help improve overall public health.

More than 130 low- and middle-income countries outside of the US will now be able to obtain this new anti-tuberculosis medicine through the procurement processes of GDF and its agent, the IDA.

Source: Johnson & Johnson

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here